Score:
6.5/10
Analyze what earned this score 🔥
Topper’s Copy
GS2
Science & Technology
10 marks
What are biosimilars? Discuss how the Biopharma Shakti initiative can help improve access to biological therapies in India.
Student’s Answer
Evaluation by SuperKalam
Demand of the Question
- Define biosimilars (their nature and characteristics)
- Discuss how BioPharma Shakti initiative improves access to biological therapies (mechanisms, impact pathways, implementation aspects)
What you wrote:
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Suggestions to improve:
- Could introduce BioPharma Shakti briefly after defining biosimilars (e.g., "To address affordability barriers in biologics, the government launched BioPharma Shakti initiative in 2024 focusing on indigenous manufacturing capabilities")
What you wrote:
Access challenges:
* Cost -> Biologics are often 20x more expensive than traditional drugs.
* Complexity -> High barriers in manufacturing, cold-chain, and regulatory approval.
Impact of BioPharma Shakti (2026)
This ₹10,000 crore initiative scales India's biopharma ecosystem:
* Infrastructure -> Upgrades NIPERs and create a network of 1000+ clinical trial sites for faster development.
* Cost Reduction -> Incentivises MSMEs to manufacture fermentation-based bulk drugs, lowering retail prices.
* Regulatory Speed -> Strengthens the CDSCO with a dedicated scientific cadre to match global approval timelines.
* Self-Reliance -> Reduces import dependence for high-value therapies like insulin and monoclonal antibodies.
Access challenges:
* Cost -> Biologics are often 20x more expensive than traditional drugs.
* Complexity -> High barriers in manufacturing, cold-chain, and regulatory approval.
Impact of BioPharma Shakti (2026)
This ₹10,000 crore initiative scales India's biopharma ecosystem:
* Infrastructure -> Upgrades NIPERs and create a network of 1000+ clinical trial sites for faster development.
* Cost Reduction -> Incentivises MSMEs to manufacture fermentation-based bulk drugs, lowering retail prices.
* Regulatory Speed -> Strengthens the CDSCO with a dedicated scientific cadre to match global approval timelines.
* Self-Reliance -> Reduces import dependence for high-value therapies like insulin and monoclonal antibodies.
Suggestions to improve:
- Could explain biosimilars' access mechanism (e.g., "Biosimilars typically cost 30-40% less than reference biologics due to abbreviated clinical trial requirements, as they don't need to repeat full Phase I-III trials")
- Can add patient-centric outcomes (e.g., "The initiative targets expanding coverage under PM-JAY and Ayushman Bharat Digital Mission for biologics like trastuzumab for cancer treatment, currently accessible to less than 15% of eligible patients")
- Could mention specific biosimilar examples already developed (e.g., "India already exports biosimilars like Bevacizumab and Rituximab; BioPharma Shakti aims to develop 20+ new molecules domestically")
What you wrote:
BioPharma Shakti bridges the "accessibility gap" by localising the value chain. It ensures immediate affordability through biosimilars while fostering long-term indigenous innovation, securing India's health sovereignty.
BioPharma Shakti bridges the "accessibility gap" by localising the value chain. It ensures immediate affordability through biosimilars while fostering long-term indigenous innovation, securing India's health sovereignty.
Suggestions to improve:
- Could add implementation challenges or way forward (e.g., "Success depends on physician awareness programs about biosimilar interchangeability and state-level procurement reforms to prioritize indigenous biologics in essential medicine lists")
You've demonstrated good structure and included specific details like budget figures. However, the core mechanism of how biosimilars improve access is entirely missing—this is a critical demand. Your BioPharma Shakti discussion needs more patient-outcome focus rather than just infrastructure listing. Strengthen the linkage between policy provisions and actual therapeutic access.
Demand of the Question
- Define biosimilars (their nature and characteristics)
- Discuss how BioPharma Shakti initiative improves access to biological therapies (mechanisms, impact pathways, implementation aspects)
What you wrote:
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Biosimilars are "near-identical" versions of original biological medicines (biologics) derived from living organisms. Unlike simple chemical generics, they are complex molecules with no clinically meaningful differences in safety or efficacy.
Suggestions to improve:
- Could introduce BioPharma Shakti briefly after defining biosimilars (e.g., "To address affordability barriers in biologics, the government launched BioPharma Shakti initiative in 2024 focusing on indigenous manufacturing capabilities")
More Challenges
View All- View Challenge
GS3
Science & Technology
1 Mar, 2026
Carbon Capture and Utilisation (CCU) is emerging as a key strategy for decarbonising hard-to-abate sectors in India. Explain the concept of CCU and examine its potential, challenges, and policy measures required for its large-scale adoption in India.
- View Challenge
GS3
Indian Polity
Yesterday
“Recent advances in HIV treatment have focused on targeting the viral capsid using long-acting drugs such as lenacapavir.”
Explain the significance of capsid-targeting therapies in controlling HIV infection. Also discuss the challenges of drug resistance and the role of combination therapy. - View Challenge
GS2
Indian Polity
27 Feb, 2026
The balance between transparency and privacy is a recurring constitutional challenge in India.
In the light of recent amendments to the RTI framework through the Digital Personal Data Protection law, examine whether the exemption of personal information undermines accountability of public authorities.
